Omega Diagnostics Shares Rise on Partnership Agreement With DAM Health – MarketWatch

By Sabela Ojea

Shares in Omega Diagnostics Group PLC on Monday rose after the company said it has signed a head-of-terms partnership agreement with DAM Health Ltd., an in-clinic and mobile provider of Covid-19 testing.

The specialist medical-diagnostics company said it will exclusively supply its Visitect professional-use Covid-19 Antigen tests to DAM Health’s clinics throughout the U.K. and elsewhere in Europe.

Omega has already received an initial purchase order in excess of 750,000 pounds ($1 million) to supply its tests to DAM Health, it said.

“There is also provision to extend this relationship beyond Europe, as DAM Health expand their international network of clinics globally,” the company said.

Shares at 0837 GMT were up 4.00 pence, or 8.1%, at 53.50 pence.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

  • Leave Comments